Despite other studies showing that inhibitors of the UPR increase TRAIL‐mediated cell death [53], overall we observed a relatively minor decrease in TRAIL expression in three of the four CLL patient samples following treatment with ONC‐212 (Figure 3A). Here, TNFSF10 is linked to B-cell chronic lymphocytic leukemia.